المؤلفون: Pagan, Carlos A, Shu, Catherine A, Crapanzano, John P, Lagos, Galina G, Stoopler, Mark B, Rizvi, Naiyer A, Heymann, Jonas J, Sonett, Joshua R, Fernandes, Helen, Saqi, Anjali

المصدر: American Journal of Clinical Pathology ; volume 154, issue 1, page 57-69 ; ISSN 0002-9173 1943-7722

الوصف: Objectives To determine concordance/discordance between morphology and molecular testing (MT) among synchronous pulmonary carcinomas using targeted next generation sequencing (NGS), with and without comprehensive molecular review (CMR), vs analyses of multiple singe genes (non-NGS). Methods Results of morphologic and MT assessment were classified as concordant, discordant, or indeterminate. For discordant cases, comprehensive histologic assessment (CHA) was performed. Results Forty-seven cases with 108 synchronous tumors were identified and underwent MT (NGS, n = 23 and non-NGS, n = 24). Histology and MT were concordant, discordant, and indeterminate in 53% (25/47), 21% (10/47), and 26% (12/47) of cases, respectively. CHA of the 10 discordant cases revised results of three cases. Conclusions There is discordance between histology and MT in a subset of cases and MT provides an objective surrogate for staging synchronous tumors. A limited gene panel is sufficient for objectively assessing a relationship if the driver mutations are distinct. Relatedness of mutations require CMR with a larger NGS panel (eg, 50 genes).

الإتاحة: https://doi.org/10.1093/ajcp/aqaa023Test
http://academic.oup.com/ajcp/article-pdf/154/1/57/33368157/aqaa023.pdfTest

المؤلفون: Heymann, Jonas J., Bulman, William A., Swinarski, David, Pagan, Carlos A., Crapanzano, John P., Haghighi, Mehrvash, Fazlollahi, Ladan, Stoopler, Mark B., Sonett, Joshua R., Sacher, Adrian G., Shu, Catherine A., Rizvi, Naiyer A., Saqi, Anjali

المصدر: Cancer Cytopathology ; volume 125, issue 12, page 896-907 ; ISSN 1934-662X 1934-6638

الوصف: BACKGROUND One immunotherapeutic agent for patients with advanced non‐small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)‐based assay that predicts response by quantifying programmed death‐ligand 1 (PD‐L1) expression. The current study assessed the feasibility of quantifying PD‐L1 expression using cytologic non‐small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens. METHODS PD‐L1 expression was quantified using the IHC‐based 22C3 pharmDx assay, with “positivity” defined as staining in ≥50% viable tumor cells; ≥ 100 tumor cells were required for test adequacy. For cytology specimens, IHC was performed on cell block sections. RESULTS A total of 214 specimens were collected from 188 patients, 206 of which (96%) were found to be adequately cellular, including 36 of 40 cytology (90%) and 69 of 72 small biopsy (96%) specimens. There was no significant difference noted with regard to the feasibility of PD‐L1 IHC on small biopsy specimens compared with surgical resection specimens ( P = .99), or between the percentage of PD‐L1‐positive cytology and histology (including surgical resection and histologic small biopsy) specimens ( P = .083). PD‐L1 expression was found to be concordant among samples from 21 of 23 patients from whom > 1 specimen was collected (91%). There also was no significant difference observed with regard to rates of PD‐L1 positivity when comparing age, sex, diagnosis, and specimen site. CONCLUSIONS Quantification of PD‐L1 expression is feasible on cytology specimens, and the results are comparable to those obtained from surgical resection and small biopsy specimens, including in matched specimens and using a single predictive IHC marker. Future studies will be necessary to determine the comparative value of other antibodies and their ability to predict response to immunotherapy. Cancer Cytopathol 2017;125:896‐907. © 2017 American Cancer Society.

الإتاحة: https://doi.org/10.1002/cncy.21937Test

المؤلفون: Wang, Tony J. C., Saad, Shumaila, Qureshi, Yasir H., Jani, Ashish, Nanda, Tavish, Yaeh, Andrew M., Rozenblat, Tzlil, Sisti, Michael B., Bruce, Jeffrey N., McKhann, Guy M., Lesser, Jeraldine, Halmos, Balazs, Stoopler, Mark B., Lassman, Andrew B., Cheng, Simon K., Isaacson, Steven R.

المصدر: Neuro-Oncology ; volume 17, issue 7, page 1022-1028 ; ISSN 1523-5866 1522-8517

الإتاحة: https://doi.org/10.1093/neuonc/nov043Test
http://academic.oup.com/neuro-oncology/article-pdf/17/7/1022/22933561/nov043.pdfTest

المؤلفون: Shu, Catherine A, Gainor, Justin F, Awad, Mark M, Chiuzan, Codruta, Grigg, Claud M, Pabani, Aliyah, Garofano, Robert F, Stoopler, Mark B, Cheng, Simon K, White, Abby, Lanuti, Michael, D'Ovidio, Frank, Bacchetta, Matthew, Sonett, Joshua R, Saqi, Anjali, Rizvi, Naiyer A

المساهمون: Genentech, Gilead Sciences, AstraZeneca

المصدر: The Lancet Oncology ; volume 21, issue 6, page 786-795 ; ISSN 1470-2045

الإتاحة: https://doi.org/10.1016/s1470-2045Test(20)30140-6
https://api.elsevier.com/content/article/PII:S1470204520301406?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1470204520301406?httpAccept=text/plainTest

المؤلفون: Chen, Lanyi Nora, Spivack, John, Cao, Thu, Saqi, Anjali, Benvenuto, Luke J., Bulman, William A., Mathew, Matthen, Stoopler, Mark B., Arcasoy, Selim M., Stanifer, Bryan P., Rizvi, Naiyer A., Shu, Catherine A.

المصدر: Lung Cancer ; volume 146, page 297-302 ; ISSN 0169-5002

الإتاحة: https://doi.org/10.1016/j.lungcan.2020.06.018Test
https://api.elsevier.com/content/article/PII:S0169500220304955?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0169500220304955?httpAccept=text/plainTest

المؤلفون: Liu-Jarin, Xiaolin, Stoopler, Mark B, Raftopoulos, Haralambos, Ginsburg, Mark, Gorenstein, Lyall, Borczuk, Alain C

المصدر: Modern Pathology ; volume 16, issue 11, page 1102-1108 ; ISSN 0893-3952

الإتاحة: https://doi.org/10.1097/01.mp.0000096041.13859.abTest
https://api.elsevier.com/content/article/PII:S0893395222046920?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0893395222046920?httpAccept=text/plainTest

المؤلفون: Xuewen Liu, Yiocia Jia, Stoopler, Mark B., Yufeng Shen, Haiying Cheng, Jinli Chen, Mansukhani, Mahesh, Koul, Sanjay, Halmos, Balazs, Borczuk, Alain C., Liu, Xuewen, Jia, Yuxia, Shen, Yufeng, Cheng, Haiying, Chen, Jinli

المصدر: Journal of Clinical Oncology; 3/10/2016, Vol. 34 Issue 8, p794-802, 9p

المؤلفون: Casper, Ephraim S., Gralla, Richard J., Kelsen, David P., Chapman, Robert A., Stoopler, Mark B., Lynch, Garrett R., Golbey, Robert B.

المصدر: International Vinca Alkaloid Symposium - Vindesine ; Contributions to Oncology ; page 350-355 ; ISSN 0250-3220 1662-2928

الإتاحة: https://doi.org/10.1159/000428659Test
https://www.karger.com/Article/Pdf/428659Test

المؤلفون: Chaudhary, Kunal R., Yan, Sherry X., Heilbroner, Samuel P., Sonett, Joshua R., Stoopler, Mark B., Shu, Catherine, Halmos, Balazs, Wang, Tony J.C., Hei, Tom K., Cheng, Simon K.

المصدر: Journal of Clinical Medicine; May2019, Vol. 8 Issue 5, p575, 1p

مصطلحات موضوعية: NON-small-cell lung carcinoma, PROPRANOLOL, ADRENERGIC receptors, CHEMORADIOTHERAPY, OTOTOXICITY, LUNG cancer

مستخلص: Introduction: Locally advanced non-small cell lung cancer (NSCLC) is highly resistant to chemoradiotherapy, and many cancer patients experience chronic stress. Studies that suggest stimulation of β-adrenergic receptors (β-AR) promotes tumor invasion and therapy resistance. We investigated whether β-AR inhibition with beta-blockers acts as a chemotherapy and radiation sensitizer in vitro and in patients treated with chemoradiation for locally advanced NSCLC. Methods: We investigated the effects of the non-selective beta-blocker propranolol on two human lung adenocarcinoma cell lines (PC9, A549) treated with radiation or cisplatin. We retrospectively evaluated 77 patients with Stage IIIA NSCLC who received induction chemoradiation followed by surgery. Pathological and imaging response, metastatic rate, and survival were analyzed using SPSS v22.0 and PrismGraphpad6. Results: Propranolol combined with radiation or cisplatin decreased clonogenic survival of PC9 and A549 cells in vitro (p < 0.05). Furthermore, propranolol decreased expression of phospho-protein kinase A (p-PKA), a β-adrenergic pathway downstream activation target, in both cell lines compared to irradiation or cisplatin alone (p < 0.05). In patients treated for Stage IIIA NSCLC, 16 took beta-blockers, and 61 did not. Beta-blockade is associated with a trend to improved overall survival (OS) at 1 year (81.3% vs 57.4%, p = 0.08) and distant metastasis-free survival (DMFS) (2.6 years vs. 1.3 years, p = 0.16). Although beta-blocker use was associated with decreased distant metastases (risk ratio (RR) 0.19; p = 0.03), it did not affect primary tumor pathological response (p = 0.40) or imaging response (p = 0.36). Conclusions: β-AR blockade enhanced radiation and cisplatin sensitivity of human lung cancer cells in vitro. Use of beta-blockers is associated with decreased distant metastases and potentially improved OS and DMFS. Additional studies are warranted to evaluate the role of beta-blockers as a chemoradiation sensitizer in locally advanced NSCLC. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)